Quantcast

Latest AMD Stories

2014-03-22 23:01:05

AMD Accelerated Muscular Development 2.0 designed by Jim Smith is a newly updated muscle building course for men who want to learn how to build more muscle mass. A full review on the site Vkool.com indicates if it is worth buying. Seattle, WA (PRWEB) March 22, 2014 AMD Accelerated Muscular Development 2.0 is a newly updated muscle building course for men who want to learn how to achieve their goals of getting ripped and strong muscles. This course also provides people with high intensity...

2014-03-12 12:29:13

Surveyed U.S. Payers Look for Substantial Delivery Achievements for Inclusion of New Agents in Formularies, According to Findings from Decision Resources Group BURLINGTON, Mass., March 12, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed U.S. and European retinal specialists ascribe a moderate to high unmet need for wet age-related macular degeneration (AMD) therapies that improve visual acuity. In line with this finding, surveyed U.S. retinal specialists expect that they...

2014-02-24 08:27:50

TARRYTOWN, N.Y., Feb. 24, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA(®) (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review of an sBLA is ten months from...

2014-02-18 08:27:28

Free AMD Guide Helps Patients Understand Risks, Proactive Measures for Eye Health ST. LOUIS, Feb. 18, 2014 /PRNewswire/ -- February is National AMD/Low Vision Awareness Month. Due to the aging Baby Boomer population, AMD, or Age-related Macular Degeneration, is expected to double by the year 2020, and patient education is critical in fighting vision loss and preserving healthy vision. EyePromise® eye vitamins is offering a complimentary patient education guide, "Getting Clear on...

2014-02-10 23:24:41

Age-Related Macular Degeneration (AMD) is the leading cause of severe vision loss in people over the age of 55 and it roughly affects 15 million Americans. Mechanicsburg, PA (PRWEB) February 10, 2014 Age-Related Macular Degeneration (AMD) is the leading cause of severe vision loss in people over the age of 55 and it roughly affects 15 million Americans. According to the National Eye Institute, AMD occurs when the small central portion of the retina, known as the macula, deteriorates....

2014-02-06 08:29:32

American Academy of Ophthalmology advises that early detection and today's treatments for common eye disease among seniors can help stop vision loss SAN FRANCISCO, Feb. 6, 2014 /PRNewswire/ -- While age-related macular degeneration (AMD) is the leading cause of new cases of blindness in Americans age 65 and older[1], seniors who develop AMD should not consider blindness in advanced age to be inevitable, according to the American Academy of Ophthalmology. During AMD Awareness Month, the...

2014-01-22 08:28:34

Patent Provides Coverage for Lpath's Anti-S1P Antibody in the Treatment of a Wide Variety of Ocular Disorders, Including Wet AMD SAN DIEGO, Jan. 22, 2014 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the U.S. Patent and Trademark Office that the company has been issued another key patent supporting its iSONEP(TM) program. The newly issued U.S. patent, No. 8,614,103, is entitled,...

2014-01-16 20:22:14

Nicox further expands North American diagnostic portfolio with access to the RetnaGene AMD test, a genetic laboratory-developed test to predict the risk of progressing to late-stage or "wet" age-related macular degeneration (AMD) SOPHIA ANTIPOLIS, France and SAN DIEGO, Jan. 16, 2014 /PRNewswire/ -- Nicox S.A. (NYSE Euronext Paris: COX), and Sequenom, Inc. (NASDAQ:SQNM), today announced that their affiliate companies (Nicox Inc. and Sequenom Laboratories) have entered into an...

2014-01-13 16:26:26

GENEVA, Jan. 13, 2014 /PRNewswire/ -- Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs announced today that Opthea Pty Ltd has entered into a commercial license agreement with Selexis covering the use of the CHO-M Cell Line and related technologies for the production of OPT-302 (formerly VGX-300), an Fc fusion protein for the treatment of wet Age-Related...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.